Women with HIV face higher rates of certain cancers: B.C. study

Researcher says HIV-positive women in treatment program are more likely to be diagnosed with invasive cervical cancer.

Woman living with HIV face elevated risk of certain cancers, a new British Columbia study has found.

By comparing databases of the B.C. Cancer Agency and the B.C. Centre for Excellence in HIV/AIDS (BC-CfE), Simon Fraser University PhD student Kate Salters discovered that HIV-positive women were far more likely to be diagnosed with invasive cervical cancer, Hodgkin’s lympohoma, non-Hodgkin’s lymphoma and Kaposi’s sarcoma.

In the case of invasive cervical cancer, the diagnosis rate for women with HIV was 24 times higher than women who don’t have HIV, said SFU professor Robert Hogg, Salters’ supervisor on the study and a senior research scientist at the BC-CfE.

Hogg told Metro there were some common traits found among the diagnosed women that leads researchers to believe more effective treatment could cut down on rates.
For example, a significant portion of the women with HIV that were also diagnosed with cancer had lapses in their HIV treatment the year before.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below